Icon Wealth Partners LLC acquired a new position in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 19,328 shares of the biopharmaceutical company’s stock, valued at approximately $700,000.
A number of other institutional investors have also modified their holdings of PFE. BlackRock Inc. grew its position in Pfizer by 2.8% in the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock worth $16,398,445,000 after acquiring an additional 12,183,218 shares during the period. Mackenzie Financial Corp grew its position in Pfizer by 29,164.7% in the fourth quarter. Mackenzie Financial Corp now owns 11,481,988 shares of the biopharmaceutical company’s stock worth $415,878,000 after acquiring an additional 11,442,753 shares during the period. Bank of New York Mellon Corp grew its position in Pfizer by 11.9% in the fourth quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock worth $2,562,162,000 after acquiring an additional 7,534,957 shares during the period. Stifel Financial Corp grew its position in Pfizer by 5,413.5% in the third quarter. Stifel Financial Corp now owns 7,360,192 shares of the biopharmaceutical company’s stock worth $262,515,000 after acquiring an additional 7,226,697 shares during the period. Finally, American Century Companies Inc. grew its position in Pfizer by 46.6% in the fourth quarter. American Century Companies Inc. now owns 22,539,888 shares of the biopharmaceutical company’s stock worth $816,395,000 after acquiring an additional 7,161,892 shares during the period. Institutional investors own 69.53% of the company’s stock.
In other Pfizer news, insider Charles H. Hill sold 42,393 shares of the firm’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total value of $1,515,973.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director W Don Cornwell sold 1,758 shares of the firm’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total value of $64,676.82. Following the completion of the sale, the director now owns 1,000 shares in the company, valued at $36,790. The disclosure for this sale can be found here. Over the last quarter, insiders sold 380,349 shares of company stock worth $13,829,340. Insiders own 0.06% of the company’s stock.
Shares of Pfizer opened at $35.89 on Friday, according to Marketbeat Ratings. The firm has a market capitalization of $213.11 billion, a PE ratio of 13.54, a P/E/G ratio of 1.78 and a beta of 0.89. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.98 and a current ratio of 1.27. Pfizer Inc. has a 12-month low of $31.67 and a 12-month high of $39.43.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.03. The business had revenue of $12.91 billion for the quarter, compared to analysts’ expectations of $13.14 billion. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The company’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period last year, the firm earned $0.69 earnings per share. analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.79%. The ex-dividend date of this dividend is Thursday, May 10th. Pfizer’s payout ratio is currently 51.32%.
PFE has been the subject of several analyst reports. SunTrust Banks reiterated a “hold” rating and issued a $40.00 price objective (up from $33.00) on shares of Pfizer in a research report on Monday, January 29th. BMO Capital Markets set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. Sanford C. Bernstein set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Pfizer in a research note on Tuesday, January 30th. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $40.08.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.